HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Chiesi widens rare disease portfolio with $1.9bn KalVista buyout

Chiesi will assume ownership of Ekterly, an on-demand pill approved for hereditary angioedema.

By Pharmaceutical Technology · Apr 30, 2026 · via Pharmaceutical Technology
Chiesi widens rare disease portfolio with $1.9bn KalVista buyout

Image: Pharmaceutical Technology

This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →

Tags
dealsformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
UCB bets $2B on Candid's T cell engager ambitions
DealsEndpoints News ↗
UCB bets $2B on Candid's T cell engager ambitions
Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in auto…
May 4, 2026
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
DealsFiercePharma ↗
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema…
May 2, 2026
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
DealsFierceBiotech ↗
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million upfront, positioning the dru…
May 1, 2026